浙江华海药业股份有限公司第九届董事会第三次临时会议决议公告

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has decided not to lower the conversion price of its convertible bonds, Huahai Convertible Bonds, despite the stock price falling below the threshold for adjustment [1][4][14]. Group 1: Board Meeting and Decisions - The third temporary meeting of the ninth board of directors was held on August 15, 2025, with all nine directors present, meeting the legal requirements for the meeting [1]. - The board unanimously approved the proposal not to lower the conversion price of the Huahai Convertible Bonds [1][4]. Group 2: Convertible Bond Details - As of August 15, 2025, the company's stock price had been below 80% of the current conversion price for at least 15 trading days within any 30 consecutive trading days, triggering the adjustment clause [4][13]. - The initial conversion price was set at 34.66 CNY per share, with the latest conversion price adjusted to 33.06 CNY per share [5][9]. - The company issued 18.426 million convertible bonds with a total amount of 1.8426 billion CNY, with a maturity of six years from the issuance date [5]. Group 3: Future Considerations - The board will not propose a downward adjustment for the conversion price in the next two months (from August 16 to October 15, 2025), even if the adjustment clause is triggered again [4][14]. - Starting from October 16, 2025, if the adjustment clause is triggered again, the board will convene to consider whether to exercise the right to adjust the conversion price [5][14].